Thomas Catinazzo Sells 734 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock

Relay Therapeutics, Inc. (NASDAQ:RLAYGet Rating) CFO Thomas Catinazzo sold 734 shares of Relay Therapeutics stock in a transaction that occurred on Thursday, July 28th. The stock was sold at an average price of $21.26, for a total transaction of $15,604.84. Following the completion of the transaction, the chief financial officer now directly owns 52,218 shares in the company, valued at $1,110,154.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Thomas Catinazzo also recently made the following trade(s):

  • On Monday, June 27th, Thomas Catinazzo sold 300 shares of Relay Therapeutics stock. The stock was sold at an average price of $20.31, for a total transaction of $6,093.00.

Relay Therapeutics Stock Down 6.8 %

NASDAQ RLAY opened at $19.02 on Monday. The stock has a market capitalization of $2.07 billion, a PE ratio of -4.82 and a beta of 1.44. The company has a 50 day moving average price of $18.08 and a two-hundred day moving average price of $22.14. Relay Therapeutics, Inc. has a 12-month low of $12.65 and a 12-month high of $38.15.

Relay Therapeutics (NASDAQ:RLAYGet Rating) last posted its earnings results on Thursday, May 5th. The company reported ($0.61) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.02. The firm had revenue of $0.42 million during the quarter. Relay Therapeutics had a negative net margin of 15,373.96% and a negative return on equity of 38.47%. During the same quarter last year, the firm earned ($0.47) earnings per share. As a group, equities analysts anticipate that Relay Therapeutics, Inc. will post -2.53 EPS for the current year.

Institutional Trading of Relay Therapeutics

A number of institutional investors have recently added to or reduced their stakes in RLAY. Nisa Investment Advisors LLC lifted its stake in Relay Therapeutics by 129.1% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,586 shares of the company’s stock valued at $57,000 after acquiring an additional 1,457 shares during the last quarter. Great West Life Assurance Co. Can lifted its stake in Relay Therapeutics by 48.9% in the first quarter. Great West Life Assurance Co. Can now owns 2,494 shares of the company’s stock valued at $79,000 after acquiring an additional 819 shares during the last quarter. Simplex Trading LLC acquired a new stake in shares of Relay Therapeutics in the first quarter worth $81,000. Ensign Peak Advisors Inc acquired a new stake in shares of Relay Therapeutics in the fourth quarter worth $143,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Relay Therapeutics by 82.6% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,112 shares of the company’s stock worth $157,000 after buying an additional 2,313 shares during the last quarter.

Wall Street Analyst Weigh In

RLAY has been the topic of several analyst reports. The Goldman Sachs Group dropped their target price on shares of Relay Therapeutics from $49.00 to $42.00 and set a “buy” rating on the stock in a research report on Tuesday, May 24th. HC Wainwright lowered their price objective on shares of Relay Therapeutics from $54.00 to $47.00 in a research report on Tuesday, May 10th. JMP Securities lowered their price objective on shares of Relay Therapeutics from $50.00 to $35.00 in a research report on Monday, May 9th. Finally, Jefferies Financial Group began coverage on shares of Relay Therapeutics in a research report on Monday, June 6th. They set an “underperform” rating and a $13.00 price objective on the stock. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $39.71.

About Relay Therapeutics

(Get Rating)

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors.

Featured Stories

Insider Buying and Selling by Quarter for Relay Therapeutics (NASDAQ:RLAY)

Want More Great Investing Ideas?

Receive News & Ratings for Relay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.